Catamaran is developing transformative off-the-shelf CAR-NK cell therapies
We are driven to realize the full potential of cell therapy by powering a key type of immune cell, Natural Killer (NK) cells, with new properties to create transformative cancer treatments for more patients. Using synthetic biology and non-viral cell engineering, Catamaran is developing highly potent allogeneic, off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies capable of treating challenging cancers, including solid tumors, by combining new functional attributes with the inherent cancer-fighting properties of NK cells.
Catamaran has developed TAILWIND®, a proprietary and integrated suite of technologies, to engineer, expand and process NK cells into safe and effective, off-the-shelf cell therapy products for multiple cancer types. We are rapidly advancing our pipeline of differentiated CAR-NK cell therapies. TAILWIND
Catamaran brings together leading-edge scientific founders and experts in NK cells, synthetic biology, manufacturing and clinical cell therapy with an internal team which has deep expertise developing cell therapies. We are supported by a broad syndicate of leading life science investors that is committed to developing innovative cell therapies. Our Leadership team
Our vision is to catalyze change in the treatment of cancer by expanding the reach of cell therapies to dramatically improve patients’ lives.